Induction of alternative lengthening of telomeres-associated PML bodies by p53/p21 requires HP1 proteins by Jiang, Wei-Qin et al.
JCB: ARTICLE
The Rockefeller University Press    $30.00
J. Cell Biol. Vol. 185 No. 5  797–810
www.jcb.org/cgi/doi/10.1083/jcb.200810084 JCB 797
Correspondence to Roger Reddel: rreddel@cmri.usyd.edu.au
Z.-H.  Zhong’s  present  address  is  Promega,  Alexandria  2015,  New  South 
Wales, Australia.
C.D. Toouli’s present address is Bio-Link Australia Pty Ltd, Locomotive Workshop, 
Eveleigh 2015, New South Wales, Australia.
Abbreviations used in this paper: 4OHT, 4-hydroxytamoxifen; ALT, alternative 
lengthening of telomeres; APB, ALT-associated PML body; ER, estrogen receptor; 
HP1, heterochromatin protein 1; LTAg, SV40 large T antigen; PCNA, proliferat-
ing cell nuclear antigen; PML, promyelocytic leukemia; SA, senescence associ-
ated; wt, wild type.
Introduction
The telomeres of human cells contain a linear tandem array of 
TTAGGG repeats bound by telomere-associated proteins, and 
are essential for chromosome stability and genomic integrity (de 
Lange, 2002). The progressive erosion of telomeres in normal 
cells during DNA replication eventually leads to the permanent 
arrest of cell division, which is referred to as replicative senes-
cence. Telomere shortening and senescence appears to be a po-
tent  tumor  suppression  mechanism  (Hanahan  and  Weinberg, 
2000; Reddel, 2000). Cancer cells bypass senescence and achieve 
unlimited replicative potential by activating a telomere length 
maintenance pathway, either telomerase (Greider and Blackburn, 
1985) or alternative lengthening of telomeres (ALT; Bryan et al., 
1995). Telomerase is active in 85% of cancers (Shay and   
Bacchetti,  1997),  and  an ALT  mechanism  is  active  in  many 
telomerase-negative tumors (Bryan et al., 1997; Henson et al., 
2005). Although molecular details of the ALT mechanism are 
just beginning to be understood (Muntoni and Reddel, 2005), 
previous studies have indicated that ALT in human cells involves 
telomere–telomere recombination (Murnane et al., 1994; Dunham 
et al., 2000). With a few exceptions (Cerone et al., 2005; Fasching 
et al., 2005; Marciniak et al., 2005; Brachner et al., 2006), the 
hallmarks of human ALT-positive cells include (1) a unique pat-
tern of telomere length heterogeneity, with telomeres that range 
from very short to greater than 50-kb long (Bryan et al., 1995), 
and (2) the presence of ALT-associated promyelocytic leukemia 
(PML) nuclear bodies (APBs) containing (TTAGGG)n DNA 
and telomere-specific binding proteins (Yeager et al., 1999).
PML bodies are found in most somatic cells; they increase 
in size and number when cells undergo cellular senescence, and 
are thus regarded as a marker of senescence (Jiang and Ringertz, 
A
lternative  lengthening  of  telomeres  (ALT)  is  a   
recombination-mediated process that maintains telo-
meres in telomerase-negative cancer cells. In asyn-
chronously dividing ALT-positive cell populations, a small 
fraction of the cells have ALT-associated promyelocytic leuke-
mia nuclear bodies (APBs), which contain (TTAGGG)n DNA 
and telomere-binding proteins. We found that restoring 
p53 function in ALT cells caused p21 up-regulation, growth 
arrest/senescence, and a large increase in cells contain-
ing APBs. Knockdown of p21 significantly reduced p53-
mediated induction of APBs. Moreover, we found that 
heterochromatin protein 1 (HP1) is present in APBs, and 
knockdown of HP1 and/or HP1 prevented p53-mediated 
APB induction, which suggests that HP1-mediated chroma-
tin compaction is required for APB formation. Therefore,   
although the presence of APBs in a cell line or tumor is an 
excellent qualitative marker for ALT, the association of APBs 
with growth arrest/senescence and with “closed” telomeric 
chromatin, which is likely to repress recombination, suggests 
there is no simple correlation between ALT activity level and 
the number of APBs or APB-positive cells.
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and are known as HP1, HP1, and HP1 (Eissenberg and   
Elgin, 2000). They are encoded by distinct genes localized on 
three different chromosomal sites (Chevillard et al., 1993), and 
they are small proteins, with <200 amino acids and molecular 
masses of 25 kD. HP1 proteins are nonhistone chromatin 
components that interact with a variety of proteins that play   
a role in chromatin remodeling and transcriptional silencing   
(Ma et al., 2001). We found that all three members of the HP1 
family—HP1, , and —are present in APBs. Knockdown of 
HP1 or HP1, but not HP1, significantly decreased the p53/p21-
mediated APB induction, which suggests that HP1- and HP1-
mediated chromatin compaction is required for APB formation.
These results indicate that APBs form in growth-arrested 
cells, and that in this context they contain “closed” telomeric 
chromatin, and are therefore not likely to be sites for telomere–
telomere recombination. These data indicate that it is unlikely 
that there is a direct correlation between APB numbers and the 
ALT activity level.
Results
Activation of the p53 pathway in  
p53-negative ALT cells induces formation 
of APBs
Large APBs are usually found in 5% of cells within asynchro-
nously growing ALT cell populations (Yeager et al., 1999). The 
proportion of APB-positive cells can be greatly increased by 
methionine starvation (Jiang et al., 2007) or by DNA-damaging 
agents (Fasching et al., 2007). In each of these cases, the treat-
ments that induced APBs also caused growth arrest (Fasching   
et al., 2007; Jiang et al., 2007). We therefore addressed the ques-
tion of whether the induction of APBs is directly related to growth 
arrest by restoring p53 function in p53-negative ALT cells. First, 
we examined the effect of activating wt p53 on APB formation 
in two p53–estrogen receptor (ER) fusion gene-transfected 
IIICF/c cell lines—c/p53ER/7 and c/p53ER/8 (abbreviated to   
C7 and C8)—in which p53 function can be activated by exposure 
to 4-hydroxytamoxifen (4OHT; Homer et al., 2005). IIICF/c is an 
ALT cell line (Rogan et al., 1995) derived from IIICF Li-Fraumeni 
syndrome fibroblasts containing one mutant (essentially null) and 
one wt TP53 allele (Warneford et al., 1992), which became im-
mortalized spontaneously via a series of genetic changes that in-
cluded loss of the wt TP53 allele (Rogan et al., 1995).
4OHT-treated C7 and C8 cells had up-regulated p21 levels 
at 24 h, and a high level of expression was maintained until day 
4 of treatment (Fig. 1, A and B). Up-regulation of p21 was not 
seen in the ethanol vehicle-treated controls, nor in a 4OHT-
treated IIICF/c control clone, c/ER/2 (abbreviated to C2), that 
had been transfected with an ER construct only (Fig. 1, A and B). 
Increased p21 expression in 4OHT-treated C7 and C8 cultures 
was accompanied by a significant increase in the proportion of 
cells containing APBs (detected here as large TRF1 foci), most 
of which were also p21 positive (Fig. 1 C and Table I). The basal 
levels of APB-positive cells in the vehicle controls were higher 
than those of most ALT cells under normal conditions of asyn-
chronous growth. This was due in part to continuous selection   
of the cells in 1 µg/ml puromycin (unpublished data), and is   
1997; Pearson et al., 2000; Ferbeyre et al., 2000). APBs are a 
subset of PML bodies that are present only in ALT cells, and are 
not found in mortal cells or telomerase-positive cells (Yeager   
et al., 1999). In addition to constitutive components of PML bod-
ies such as PML and Sp100, and telomeric DNA and telomere-
associated proteins such as TRF1, TRF2, TIN2, and RAP1 
(Yeager et al., 1999; Wu et al., 2003; Jiang et al., 2007), they 
also contain other proteins involved in DNA replication, re-
combination, and repair including RAD51, RAD52, and RPA 
(Yeager et al., 1999); RAD51D (Tarsounas et al., 2004); BLM 
(Yankiwski et al., 2000; Stavropoulos et al., 2002); WRN (Johnson 
et al., 2001); RAP1 and BRCA1 (Wu et al., 2003); MRE11, 
RAD50, and NBS1 (Wu et al., 2000; Zhu et al., 2000); ERCC1 
and XPF (Zhu et al., 2003); hRAD1, hRAD9, hRAD17, and 
hHUS1 (Nabetani et al., 2004); Rif1 (Silverman et al., 2004); 
and hnRNP A2 (Moran-Jones et al., 2005). Formation of APBs 
requires NBS1, which recruits MRE11, RAD50, and BRCA1 
into these structures (Wu et al., 2003; Jiang et al., 2005). We in-
duced APB accumulation with methionine restriction, and used 
RNAi-based screening to extend the list of proteins required for 
APB formation to include PML, TRF1, TRF2, TIN2, RAP1, 
MRE11, and RAD50 (Jiang et al., 2007). It was recently found 
(Potts and Yu, 2007) that the structural maintenance of chromo-
somes SMC5/6 complex localizes to APBs in ALT cells and su-
moylates TRF1 and TRF2, and this plays an essential role in 
APB formation. It has long been suggested that APBs may have 
an integral role in the ALT mechanism (Yeager et al., 1999; 
Grobelny et al., 2000; Wu et al., 2000; Molenaar et al., 2003; 
Wu et al., 2003), and, consistent with this suggestion, inhibition 
of ALT in some somatic cell hybrids formed by fusion of ALT 
and telomerase-positive cell lines resulted in a substantial de-
crease in APBs (Perrem et al., 2001). Furthermore, our recent 
study showed that inhibition of ALT is accompanied by sup-
pression of APBs, providing evidence for a direct link between 
APBs and ALT activity (Jiang et al., 2005; Zhong et al., 2007).
Although we speculated that the increase in APB-positive 
cells after methionine starvation may have resulted from reduced 
levels of methylation at telomeric and subtelomeric regions, and 
a consequent increase in telomeric recombination events (Jiang   
et al., 2007), it also remained a possibility that the increase in 
APBs was instead related to cell cycle arrest. To clarify this, we 
examined the effect of activating wild-type (wt) p53 on APB for-
mation in p53-negative ALT cells. We found that activation of 
p53 up-regulated p21, and caused growth arrest and senescence, 
accompanied by a very large increase in APB formation. This 
upsurge in APB numbers was substantially prevented by siRNA-
mediated knockdown of p21, indicating that p21 is a major down-
stream p53 effector of APB induction. Moreover, both p21 and its 
binding partner proliferating cell nuclear antigen (PCNA) were 
found to be present inside APBs, but knockdown of PCNA did 
not affect p53/p21-mediated APB induction.
Because APBs contain telomeric chromatin, which is het-
erochromatic in nature, we have also investigated whether APBs 
are associated with the heterochromatin protein 1 (HP1) family. 
The HP1 family plays a critical role in establishing and maintain-
ing transcriptionally inactive heterochromatin, including that of 
telomeres. Three mammalian HP1 proteins have been identified 799 p53/p21-MEDIATED INDUCTION OF APBS REQUIRES HP1 • Jiang et al.
Figure 1.  Induction of APBs in C7 and C8 cells 
upon 4OHT-mediated activation of p53. (A) p21 
was up-regulated in C7 and C8 cells, which ex-
press a p53-ER fusion protein, after 1, 2, or 4 d 
of 4OHT-treatment, but not in C2 cells, which ex-
press a control ER protein. The Western blot was 
probed with the indicated antibodies. (B) p21 
staining of C2 and C8 cells treated with 4OHT 
or ethanol vehicle for 4 d. Only 4OHT-treated 
C8 cells showed strong p21 staining. (C) Double 
immunostaining of TRF1 and p21 in C7 and C8 
cells treated with 4OHT or ethanol vehicle for 
4 d. Large TRF1 foci were induced in cells posi-
tive for p21. Bars, 20 µm.
presumably also partly due to a low level of leakiness of the 
p53ER inducible system.
To demonstrate that the TRF1 foci were APBs, we showed 
that they also contained telomeric DNA, TRF2, and PML pro-
tein (Fig. 2). APBs are usually somewhat larger than the PML 
bodies in ALT cells that do not contain telomeric contents, and 
the quantity of telomeric DNA and telomeric binding proteins 
that they contain is often greater than the amount present at in-
dividual telomeres (Fig. 2). Because of a tight correlation between 
foci of telomeric DNA and of TRF1 or TRF2, APBs can be de-
tected interchangeably by either telomeric FISH or immuno-
staining of TRF1 or TRF2 (Jiang et al., 2005, 2007). In this 
study, APBs were generally detected by visualizing TRF1 or 
TRF2 within a PML body, but were also identified as large, 
bright TRF1, TRF2, or telomeric DNA foci (Fig. 2). The 4OHT-
treated C7 and C8 cultures contained 2.6-fold more APB-positive 
cells than the control cultures that were treated with ethanol ve-
hicle alone (Table I). Changes in the proportion of APB-positive 
cells were minimal in 4OHT-treated C2 cells (Table I).
After 4 d of 4OHT treatment, many of the cells had under-
gone the characteristic morphological changes of senescence and 
stained positive for senescence-associated (SA) -galactosidase 
(SA--gal) activity (Fig. 3 A). Most of the cells that were mor-
phologically senescent contained APBs, as illustrated in Fig. 3 B, JCB • VOLUME 185 • NUMBER 5 • 2009   800
Because knockdown of LTAg in IIICF-T/B3 cells restored 
the function not only of p53 but also of other proteins, including 
the retinoblastoma protein (pRb) family members that also bind 
to LTAg, we used another ALT cell line, IIICF-402DE/D2, as a 
control to determine whether pathways other than p53 were 
involved. IIICF-402DE/D2 was, like IIICF-T/B3, derived from 
the same parental IIICF cells, but was transfected with a mutant 
SV40 early region plasmid, 402DE with a D→E mutation at 
LTAg amino acid 402 (Maclean et al., 1994). This mutant LTAg 
is disabled for p53 binding, and as a consequence, the wt TP53 
allele was deleted spontaneously during immortalization of 
IIICF-402DE/D2 cells. Therefore, no p53 expression was de-
tectable before or after LTAg knockdown (Fig. 4 A).
As expected, p21 expression increased in IIICF-T/B3 but 
not in IIICF-402DE/D2 cells after siRNA-mediated knockdown 
of LTAg (Fig. 4, A and B), and this induced a senescent pheno-
type in IIICF-T/B3 (Fig. S1) but not IIICF-402DE/D2 cells (un-
published data). Notably, induction of senescence was accompanied 
by a significant increase in APB formation in IIICF-T/B3 cells 
after a 4-d period of SV40T siRNA treatment (Fig. 4 C). Con-
sistent with the results from 4OHT-treated C7 and C8 cells, 
most of the APB-positive IIICF-T/B3 cells were p21 positive 
and BrdU negative (Table II and Fig. S2). APBs were found in 
55% of the IIICF-T/B3 cells that were depleted of LTAg, as 
compared  with  10%  of  the  IIICF-402DE/D2  cells  where 
LTAg was undetectable (Fig. 5 C and Table III). This was not 
caused by an intrinsic difference in the ability of the two cell 
lines to form APBs because, despite the difference in p53 status, 
IIICF-402DE/D2 and IIICF-T/B3 cultures displayed a similar 
and triple staining for BrdU, p21, and TRF1 revealed that most 
of the APB-positive cells were p21 positive and BrdU negative 
(Fig. 3 C and Table II). Based on these data, we conclude that 
the APBs that were induced upon restoration of p53 activity in 
C7 and C8 cultures mostly occurred in growth-arrested or phe-
notypically senescent cells.
p21 is a key downstream effector of p53 
for APB induction
To confirm the involvement of the p53 pathway in APB induc-
tion, we also examined APB formation in an ALT cell line, 
IIICF-T/B3, that was established by transfecting IIICF cells with 
an SV40 early region expression plasmid (Maclean et al., 1994); 
these cells retain a wt TP53 allele. We restored p53 function by 
knockdown of SV40 large T antigen (LTAg) with an siRNA 
against the SV40 early region transcripts (SV40T siRNA). 
Figure 2.  APBs can be detected interchangeably by either telomeric FISH or immunostaining of TRF1 or TRF2. After 4 d of 4OHT treatment, APBs were 
induced in C7 and C8 cells, where colocalization was observed between prominent TRF1 foci and large PML bodies (top), between telomeric DNA and 
TRF1 foci (middle), and between TRF1 and TRF2 foci (bottom). Bar, 20 µm.




c/ER/2 EtOH 26/239 (10.9)
c/ER/2 4OHT 28/215 (13.0)
c/p53ER/7 EtOH 41/238 (17.2)
c/p53ER/7 4OHT 110/234 (47.0)
c/p53ER/8 EtOH 47/258 (18.2)
c/p53ER/8 4OHT 108/240 (45.0)
aCells were treated with 1 µM 4OHT or 0.01% ethanol (EtOH) for 4 d before 
being fixed for immunostaining.801 p53/p21-MEDIATED INDUCTION OF APBS REQUIRES HP1 • Jiang et al.
Figure  3.  Induction  of  APBs  is  associated 
with p53/p21-mediated senescence. (A) SA--
gal staining of C2, C7, and C8 cells treated 
with 4OHT or ethanol vehicle for 4 d. SA--
gal  expression  was  found  in  4OHT-treated 
C7 and C8 cells. (B) TRF1 and DAPI staining 
of C8 cells treated with 4OHT for 3 d. APBs 
were found in phenotypically senescent cells. 
(C) Triple immunostaining of TRF1, BrdU, and 
p21 in C7 and C8 cells after treatment with 
4OHT for 4 d, and with BrdU for 24 h before 
the end of 4OHT treatment. APBs (visualized 
here as large TRF1 foci) were found mainly in 
cells staining positive for p21 and negative for 
BrdU. Bars: (A) 100 µm; (B and C) 20 µm.






b p21+ (%) BrdU (%) p21+ and BrdU (%)
C7 (4OHT) 150 132 (88.0) 129 (86.0) 122 (81.3)
C8 (4OHT) 127 105 (82.7) 106 (83.5) 94 (74.0)
IIICF-T/B3(SV40T-siRNA) 153 128 (83.7) 131 (85.6) 115 (75.2)
aCells were treated with 1 µM 4OHT or 10 nM SV40T siRNA for 4 d, and BrdU was added 24 h before the end of treatment.
bOnly cells that were APB positive were examined for BrdU and p21.JCB • VOLUME 185 • NUMBER 5 • 2009   802
reduction in the proportion of IIICF-T/B3 cells that became se-
nescent (Fig. S1). Importantly, induction of APBs was reduced 
by >50% when IIICF-T/B3 cells were treated with siRNAs 
against both SV40T and p21 (Fig. 5 C and Table III). p53 siRNAs 
(p53-9 or p53-p) antagonized induction of APBs by SV40T 
siRNA to the same extent as p21 siRNAs (Fig. 5 B and Table III). 
These data indicate that p21 is a major downstream effector of 
p53 for APB formation.
p21 and its binding partners PCNA and 
Cdk2 are localized in APBs
We found that p21 was present inside APBs in 30% of the 
APB-positive cells where the p53 pathway was restored (Fig. 6 A 
and Table S2), showing for the first time that a cell cycle regula-
tory protein was physically associated with APBs and PML 
bodies. To confirm the immunostaining results, we used two   
increase in the proportion of APB-positive cells in response to 
methionine starvation (Table S1). APBs were also induced in 
another  SV40-immortalized  ALT  cell  line,  JFCF-6/T.1J/1D, 
upon knockdown of SV40 LTAg (Table III), but no APBs were 
found in the isogenic control telomerase-positive cell line, 
JFCF-6/T.1J/6B, which was SV40-immortalized from the same 
parental cell as the JFCF-6/T.1J/1D cells (Fig. S3).
Because a close correlation was found between APB for-
mation and high levels of p21 (Figs. 1 C and 4 C; and Table II), 
we tested whether p21 plays an important role in p53-mediated 
induction  of APBs  in  p53-negative ALT  cells.  p21  siRNAs 
(p21-6 or p21-7) were used in combination with SV40T siRNA 
to simultaneously knock down p21 and LTAg in IIICF-T/B3 
cells. Western analysis showed that the induction of p21 by 
knockdown of LTAg was effectively blocked by either p21-6 or 
p21-7 siRNAs (Fig. 5, A and B). This resulted in a substantial 
Figure 4.  Induction of APBs in SV40-immortal-
ized ALT cells by siRNA-mediated knockdown of 
LTAg. (A) Western blots showed decreased LTAg 
in both IIICF-T/B3 (containing wt LTAg and one 
wt TP53 allele) and IIICF-402DE/D2 (containing 
mutant LTAg that does not bind p53, and no wt 
TP53 alleles) cells 48 h after SV40T siRNA trans-
fection.  Treatment  with  SV40T  siRNA  induced 
p21 in IIICF-T/B3 but not in IIICF-402DE/D2 
cells. The blots were probed with the indicated 
antibodies.  (B)  Double  immunofluorescence  of 
SV40T and p21 in IIICF-T/B3 and IIICF-402DE/
D2 cells treated with SV40T or control siRNAs for 
4 d. Strong p21 staining was detected in IIICF-T/
B3 cells depleted of SV40T. (C) IIICF-T/B3 cells 
were triple stained for TRF1, p21, and SV40T   
4 d after SV40T siRNA transfection. APBs (visual-
ized here as large TRF1 foci) were observed in 
cells with high levels of p21. Bars: (B) 100 µm; 
(C) 20 µm.803 p53/p21-MEDIATED INDUCTION OF APBS REQUIRES HP1 • Jiang et al.
to PCNA, Cdk2 was not present inside APBs in p53-negative 
IIICF/c cells (unpublished data), which indicates that it is un-
likely to be involved in APB formation. Because of its involve-
ment in DNA repair, we further investigated the role of PCNA   
by transfecting IIICF-T/B3 cells with a combination of SV40T 
siRNA and PCNA siRNAs (PCNA-1 or PCNA-6), the effectiveness 
of which was demonstrated by Western analysis (Fig. 6 C). We 
found that knockdown of PCNA did not block APB induction in 
cells treated with SV40T siRNA (Fig. 6 D), which contrasted 
with the results from the control where p21 siRNA was used in-
stead of PCNA siRNA (Table III). These results indicate that 
PCNA is not required for APB formation.
HP1 and HP1, but not HP1, are 
required for APB formation
Upon cellular senescence, heterochromatin becomes highly com-
pacted by a process that involves HP1 family members (Funayama 
different p21 antibodies (see Materials and methods), and checked 
the specificity of each antibody by siRNA knockdown. This lo-
calization of p21 appears to be specific to ALT cells and APBs, 
as it was not seen in PML bodies in senescent normal IMR-90 
fibroblasts (unpublished data). To determine what type of role 
p21 plays inside APBs, we first examined the localization of its 
binding partner PCNA in IIICF-T/B3 cells upon knockdown of 
LTAg because PCNA, along with p21, has been suggested to be 
involved in DNA repair (Li et al., 1994; Perucca et al., 2006). 
Triple immunostaining of p21, PCNA, and TRF1 revealed the 
coexistence of PCNA and p21 inside APBs, but only in a frac-
tion of APB-positive cells (Fig. 6 B). The presence of PCNA in 
APBs did not require restoration of the p53 pathway because it 
was also found in APBs within the parental ALT cell line, IIICF/c, 
which is essentially p53 null (Fig. S4 A). In addition, p21 co-
localized with another of its binding partners, Cdk2, inside APBs 
in a fraction of APB-positive cells (Fig. S4 B). However, in contrast 
Figure 5.  p21 is the major downstream effector of p53 for APB induction. (A and B) Induction of p21 in IIICF-T/B3 cells by SV40T siRNA was effectively 
abrogated by siRNAs against p21 (p21-6 and p21-7) or p53 (p53-p and p53-9). The Western blots were probed with the indicated antibodies. (C) Triple 
immunostaining of TRF1, p21, and SV40T in IIICF-T/B3 and IIICF-402DE/D2 cells treated with the indicated combinations of siRNAs for 4 d. p21 siRNA 
(p21-7) largely prevented SV40T siRNA-mediated induction of APBs. C, control siRNA; T, SV40T siRNA. Bar, 20 µm.JCB • VOLUME 185 • NUMBER 5 • 2009   804
of p21, growth arrest, and senescence, as well as a large   
increase in APB formation. These observations suggest that me-
thionine restriction–induced APB induction (Jiang et al., 2007) 
results from growth arrest rather than some other mechanism 
such as decreased DNA methylation. They also indicate that 
the use of cell cycle blocking agents may not be an appropriate 
approach for determining whether there is a relationship be-
tween the cell cycle phase and expression of APBs. In this study, 
restoration of p53 function resulted in APB induction in cells 
that were arrested predominantly in the G1 phase of the cell 
cycle (unpublished data), but because APBs are also found in 
cells arrested in late S/G2/M phases of the cell cycle (Grobelny 
et al., 2000; Wu et al., 2000), it seems likely that the correlation 
is between APB formation and growth arrest rather than with a 
particular cell cycle phase. Although large APBs are found in 
5% of cells within asynchronously dividing ALT cell popula-
tions (Yeager et al., 1999), it seems likely that most of these have 
spontaneously undergone growth arrest and are either quies-
cent or senescent, as most APB-positive cells in these popula-
tions do not incorporate BrdU within a time period exceeding 
the mean cell doubling time, and many of these also display the 
enlarged, flattened morphology characteristic of senescence 
(unpublished data).
It has previously been shown that overexpression of p53 
can induce a senescence-like growth arrest in tumor cells (Sugrue 
et al., 1997; Ling et al., 2000), and that activation of endogenous 
p53 in the U-2 OS ALT cell line can induce senescence (Stagno 
D’Alcontres et al., 2007). Among the multiple genes activated by 
p53, p21 is a crucial transcriptional target of p53 and a mediator of 
p53-dependent senescence (Brown et al., 1997). p21 is a pleiotropic 
inhibitor of different cyclin/Cdk complexes (Dotto, 2000), the in-
duction of which can cause cell cycle arrest and senescence in nor-
mal cells (Noda et al., 1994) and phenotypic senescence in tumor 
cells (Chang et al., 1999; Fang et al., 1999; Kagawa et al., 1999; 
Wang et al., 1999). It has also been shown that infection of sponta-
neously immortalized Li-Fraumeni syndrome cells, either telo-
merase positive or negative, with a p21 retroviral vector resulted in 
senescence (Vogt et al., 1998). Consistent with these results, our 
data showed that high levels of p21 correlated with p53-mediated 
senescence in ALT cells. Moreover, knockdown of p21 inhibited 
induction of the senescent phenotype and suppressed p53-mediated 
induction of APBs, which is consistent with p21 being a major 
regulator of p53-mediated senescence, and indicates that p21 is 
a major downstream effector of p53 for APB induction.
Our finding that p21 is present inside APBs was not entirely 
unexpected, as APBs contain substantial amounts of telomeric 
DNA, some of which is linear and may be recognized as DNA 
damage (Fasching et al., 2007). Although it is a cell cycle regula-
tory protein, p21, along with PCNA, has been suggested to play a 
role in DNA repair (Li et al., 1994; Perucca et al., 2006). The co-
existence of PCNA and p21 inside APBs in a small fraction of 
ALT cells suggests that p21 and PCNA may be involved in DNA 
repair inside APBs. Nevertheless, PCNA was not required for   
formation of APBs because knockdown of PCNA did not affect 
p53/p21-mediated APB induction. Moreover, the presence of 
p21 and another of its binding partners, Cdk2, inside APBs in 
p53-reconstituted but not p53-negative ALT cells suggests that 
and Ishikawa, 2007). APBs contain telomeric chromatin, which 
is heterochromatic in nature. We therefore addressed the ques-
tion of whether chromatin compaction is required for APB for-
mation upon p53/p21-mediated growth arrest/senescence. We 
examined the localization of HP1 family proteins in C7, C8, and 
IIICF-T/B3 cells upon restoration of the p53 pathway, and found 
that all three members of the HP1 family—HP1, HP1 and 
HP1—are present in APBs (Fig. 7 A). This led to a further analy-
sis to determine whether members of the HP1 family are re-
quired for APB formation. Double knockdown of LTAg and HP1 
proteins was performed in IIICF-T/B3 cells with SV40T siRNA 
and the siRNAs against HP1 (HP1 or HP1-2), HP1 (HP1-1 
or HP1-4), or HP1 (HP1-2 or HP1-6), the effectiveness   
of which was demonstrated by Western analysis (Fig. 7 B). We 
found that knockdown of HP1 or HP1 inhibited the p53/p21-
mediated induction of APBs by 40%, whereas knockdown of 
HP1 only slightly reduced the increase in APBs (Table IV). 
Moreover, simultaneous knockdown of HP1 and HP1 had an 
additive effect in inhibiting APB formation by 60% (Fig. 7 C 
and Table IV). To know whether HP1 proteins are involved in 
APB formation in the absence of p53, we performed a similar set 
of experiments on IIICF/c cells that were p53 negative. HP1 pro-
teins were found to be present in APBs in exponentially dividing 
or methionine-restricted IIICF/c cells (Fig. S5 and unpublished 
data). Also, simultaneous knockdown of HP1 and HP1 largely 
prevented induction of APBs in methionine-restricted cells   
(Fig. S5 B and Table S3). In summary, the data indicate that HP1 
and HP1 are required for APB formation.
Discussion
Nearly all ALT cell lines have a dysfunctional p53 pathway, 
and consequently it has been speculated that mutation of p53 
might be a contributing factor for ALT activation (Henson et al., 
2002; Razak et al., 2004). In the present study, we have shown 
that restoration of p53 function in ALT cells causes up-regulation 
Table III.  Proportion of APB-positive cells after siRNA treatment
Cell lines siRNA treatment
a APB+/SV40T
b (%)
IIICF-T/B3 SV40T + C 98/170 (57.6)
IIICF-402DE/D2 SV40T + C 20/176 (11.4)
IIICF-T/B3 SV40T + p21-7 43/172 (25.0)
IIICF-402DE/D2 SV40T + p21-7 18/179 (10.1)
JFCF-6/T.1J/1D SV40T + C 85/137 (62.0)
JFCF-6/T.1J/1D SV40T + p21-6 36/132 (27.3)
IIICF-T/B3 SV40T + C 87/156 (55.8)
IIICF-T/B3 SV40T + p21-6 34/158 (21.5)
IIICF-T/B3 SV40T + p21-7 38/151 (25.2)
IIICF-T/B3 SV40T + p53-9 29/153 (19.0)
IIICF-T/B3 SV40T + p53-p 38/160 (23.8)
IIICF-T/B3 SV40T + PCNA-1 81/154 (52.6)
IIICF-T/B3  SV40T + PCNA-6 82/149 (55.0)
C, nonsilencing control siRNA.
aCells were treated with 10 nM siRNA per target for 4 d before being fixed for 
immunostaining.
bOnly cells that were negative by immunostaining for SV40T were examined 
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most likely involved in reestablishment of the heterochromatic 
state of late-replicating juxtacentromeric satellite DNA (Luciani 
et al., 2006). Our demonstration that knockdown of HP1 and/or 
HP1 significantly inhibited p53/p21-mediated APB induction 
and also inhibited formation of APBs in methionine-restricted 
cell populations shows for the first time that these proteins are 
not only present in APBs but are also required for their forma-
tion, and suggests that HP1- and HP1-mediated chromatin 
compaction is involved in this process. It should be pointed out 
that knockdown of HP1 has only minor effects on APB for-
mation as compared with HP1 and HP1. This could be due 
to HP1 isoform-specific effects on telomeres, which have been 
demonstrated by a previous study on overexpression of HP1 
isoforms in telomerase-positive cells (Sharma et al., 2003).
It has previously been shown that the MRE11/RAD50/
NBS1 (MRN) complex (Wu et al., 2003; Jiang et al., 2005) 
and shelterin proteins (Jiang et al., 2007) are required for APB 
localization of both proteins into PML bodies is unlikely to be a 
prerequisite for APB formation.
We have also shown here for the first time that all three 
members of the HP1 protein family, HP1, , and , were 
present in APBs. This is in agreement with previous findings 
that human and mouse telomeres are enriched for HP1 (Koering   
et al., 2002; Garcia-Cao et al., 2004; Gonzalo et al., 2005, 2006). 
Upon cellular senescence, heterochromatin becomes highly com-
pacted by a process that involves HP1 family members (Funayama 
and Ishikawa, 2007), which have previously been shown to 
associate with PML bodies (Seeler et al., 1998), including in 
normal senescent fibroblasts (Zhang et al., 2005). HP1 proteins 
have also been found in the giant PML body that associates with 
juxtacentromeric satellite DNA during G2 phase in cells from 
individuals with immunodeficiency, centromeric instability, and 
facial dysmorphy (ICF) syndrome, and on the basis of this cell 
cycle timing, the authors suggested that the HP1 proteins are 
Figure 6.  Presence of p21 and its binding part-
ner, PCNA, in APBs. (A) Double immunostaining 
of TRF1 and p21 in C7 cells treated with 4OHT 
for 1 d, C8 cells treated with 4OHT for 4 d, and 
IIICF-T/B3 cells treated with a combination of 
SV40T and control siRNAs for 4 d. p21 was de-
tected inside APBs. (B) Triple immunostaining of 
TRF1, p21, and PCNA in IIICF-T/B3 cells treated   
with a combination of SV40T and control siRNAs 
for 3 d. p21 and PCNA were colocalized in 
APBs. (C) The effectiveness of PCNA siRNAs 
(PCNA-1 and PCNA-6) was demonstrated by 
Western blots. (D) Triple staining of TRF1, SV40T, 
and PCNA in IIICF-T/B3 cells treated with com-
bination of SV40T and PCNA-6 siRNAs for 4 d. 
APBs were still detected in cells depleted of both 
SV40T and PCNA. Bars, 20 µm.JCB • VOLUME 185 • NUMBER 5 • 2009   806
possibility is suggested by the observation that MRN is required   
for recruitment of HP1 proteins to the Drosophila telomere 
(Ciapponi et al., 2004); at mammalian telomeres, although HP1 
and MRN proteins are known to be present (for review see 
Blasco, 2007), a role for MRN in recruitment of HP1 has not yet 
been demonstrated. Based on these data and the known role of 
HP1 proteins in compaction of chromatin, we propose that the 
role of HP1 proteins in formation of APBs may be to compact 
the telomeric DNA, possibly as a prerequisite for its transloca-
tion to PML bodies, and this may be mediated at least in part by 
some indirect interactions of HP1 proteins with telomeric DNA 
via shelterin or MRN proteins. Furthermore, as proposed for juxta-
centromeric satellite DNA in G2 (Luciani et al., 2006), it seems 
possible that HP1 may tether telomeric DNA into PML bodies 
by interacting with sumoylated proteins via ATRX and DAXX.
formation, although under different experimental conditions, 
depletion of TRF2 did not always inhibit APB formation (Stagno 
D’Alcontres et al., 2007). We therefore proposed a model in 
which telomeric DNA binds to the MRN complex via the shel-
terin component RAP1, and then translocates to PML bodies to 
form APBs (Jiang et al., 2007). The data presented here show-
ing that HP1 proteins are also required for APB formation raise 
the question of what role they play in this process, and whether 
shelterin and MRN proteins may interact with HP1 proteins at telo-
meres. HP1 proteins are usually recruited to chromatin through 
their affinity for trimethylated H3K9 residues (Lachner et al., 2001; 
Garcia-Cao et al., 2004), but it is also possible that this occurs 
through the interactions between TRF1 and the HP1-interacting 
developmental regulator SALL1 (Netzer et al., 2001) or be-
tween TIN2 and HP1 (Kaminker et al., 2005). Another interesting 
Figure 7.  HP1 localization in APBs and effects on APB formation of HP1 depletion. (A) Triple immunostaining showed colocalization between HP1 and 
APBs in IIICF-T/B3 cells treated with SV40T siRNA for 4 d (top), between HP1 and APBs (middle), and between HP1 and APBs (bottom) in C7 cells 
treated with 4OHT for 4 d. (B) The effectiveness of individual siRNAs for HP1 (HP1 and HP1-2), for HP1 (HP1-1 and HP1-4), and for HP1 (HP1-2 
and HP1-6) was demonstrated by immunoblotting. The black lines indicate that redundant lanes within the same gel have been spliced out. (C) IIICF-T/B3 
cells were triple stained for TRF1, p21, and SV40T 4 d after transfection of the indicated combinations of siRNAs. Simultaneous treatment with HP1 (HP1-2) 
and HP1 (HP1-6) siRNAs prevented SV40T siRNA-mediated induction of APBs. C, control siRNA; T, SV40T siRNA. Bars, 20 µm.807 p53/p21-MEDIATED INDUCTION OF APBS REQUIRES HP1 • Jiang et al.
For p53 induction experiments, C2, C7, and C8 cells were seeded 
in phenol red–free DME and grown to 30–40% confluency. The cell cul-
tures were treated with 1 µm 4OHT or 0.01% ethanol as a vehicle control. 
After various time periods, cells were either fixed for immunostaining or 
harvested for isolation of protein.
For methionine restriction, cells were seeded in normal medium and 
grown to 30–40% confluency. Cells were washed once with methionine-free 
medium before changing to this medium. After 4 d, cells were fixed for   
immunostaining. Methionine-deficient medium was reconstituted from methi-
onine- and cystine-deficient DME (Invitrogen) by adding l-cystine (48 mg/liter; 
Sigma-Aldrich).
Antibodies
The following antibodies were used in this study: mouse anti-p21, anti-TRF2, 
anti-Cdk2, and anti-BrdU (BD); goat anti-p21 (R&D Systems); rabbit anti-
p53 (FL-393), goat anti-PCNA (C-20), goat anti-PML (N-19), and mouse 
anti-PML (Santa Cruz Biotechnology, Inc.); rabbit anti-PML and anti-Sp100 
(Millipore); mouse anti-TRF2 and anti-HP1 (Millipore); rabbit anti-HP1, 
anti-HP1, and anti-HP1 (Cell Signaling Technology); and rabbit anti-
HP1 and anti-HP1 (Proteintech Group). Mouse anti-SV40T (PAb108) was 
purified from the supernatant of hybridoma TIB-230 (American Type Culture 
Collection), and polyclonal anti-TRF1 rabbit serum was raised against a 
TRF1 peptide, residues 13–35.
RNAi
The following siRNAs were designed and synthesized by QIAGEN: for   
p21,  5-CAGTTTGTGTGTCTTAATTAT-3  (p21-6)  and  5-CTGGCATTAG-
AATTATTTAAA-3 (p21-7); for p53, 5-AAGGAAATTTGCGTGTGGAGT-3   
(p53-9);  for  PCNA,  5-ATGGATTTAGATGTTGAACAA-3  (PCNA-6);  for 
Sp100,  5-CAGGAAATTATGATAAACTCA-3  (Sp100-1);  for  HP1,   
5-AAGGGAAGGAGTTCTACTTGT-3 (HP1-1) and 5-AAGGACTAAGC-
CTGTTCATAA-3 (HP1-4); and for HP1, 5-AAAGTACTAGATCGAC-
GTGTA-3 (HP1-2) and 5-CTGGTTACTTTGAACAAATAA-3 (HP1-6). 
The following siRNAs were synthesized by QIAGEN: for SV40T, 5-AAA-
ATTGTGTACCTTTAGCTT-3 (Harborth et al., 2001); for p53 (p53-p),   
5-CGGCATGAACCGGAGGCCCAT-3 (Martinez et al., 2002); for PCNA 
(PCNA-1), 5-GAGGAGGAAGCTGTTACCATA-3 (Senga et al., 2006); 
and for HP1 (HP1 and HP1-2), 5-AACCTGAGAAAAACTTGGATT-3 
(Obuse et al., 2004) and 5-GAGGAGCACAATACTTGGGAA-3 (Sripathy   
et al., 2006). The nonsilencing control siRNA was obtained from QIAGEN.
To determine the extent of knockdown, cells were transfected with 
10 nM siRNA per target gene using HiPerFect transfection reagent accord-
ing to the manufacturer’s instructions (QIAGEN). For Western analysis, 
cells were seeded into 6-well plates 1–2 d before siRNA transfection. After 
transfection for 48 h, cells were harvested for protein isolation.
APB screening in SV40-immortalized cell lines by RNAi
Cells were seeded into 4-well chamber slides (Thermo Fisher Scientific) 2 d 
before transfection of siRNAs. For double or triple knockdown experiments, 
10 nM siRNA per target gene, along with 10 nM SV40T siRNA, was trans-
fected into cells using HiPerFect. 4 d later, cells were fixed and immunostained 
for SV40T, p21, and TRF1 (large foci of which are recognized as APBs). 
Finally, APB positivity was scored for the cells in which SV40T was depleted.
Immunostaining, BrdU labeling, telomere FISH,  
and fluorescence microscopy
Cells grown in 4-well chamber slides were fixed for 15 min in 2% paraformal-
dehyde at room temperature, then permeated with methanol/acetone (1:1) at 
20°C for 15 min. Cells were incubated overnight with primary antibodies at 
4°C, then incubated with fluorescently conjugated secondary antibodies at 
room temperature for 40 min. In some cases, DAPI (Sigma-Aldrich) was in-
cluded in the secondary incubation to visualize DNA. Finally, the preparations 
were mounted in anti-fading medium containing DABCO (Sigma-Aldrich) or 
medium consisting of glycerol/PBS (70%:30%). The secondary antibodies 
used were as follows: FITC- or Texas red–conjugated goat anti–mouse; FITC- or 
Texas  red–conjugated  goat  anti–rabbit;  7-amino-4-methylcoumarin-3-acetic 
acid (AMCA)-, FITC-, or Texas red–conjugated donkey anti–mouse; AMCA-, 
FITC- or Texas red–conjugated donkey anti–rabbit; and AMCA- or Texas red–
conjugated donkey anti–goat (Jackson ImmunoResearch Laboratories).
For BrdU labeling of growth-arrested cells, cells were grown in 4-well 
chamber slides to 30–40% confluency and then treated with 1 µM 4OHT or 
10 nM SV40T siRNA for 4 d. 10 µM BrdU (Roche) was added to the culture 
medium for 24 h before fixation. The cells were fixed as described in the 
previous paragraph, then incubated with 2 µg/ml DNase I (Sigma-Aldrich) 
for 30 min at 37°C before incubation with primary antibodies against BrdU, 
p21, and TRF1.
APBs have long been suggest to play an integral role in 
the ALT mechanism (Yeager et al., 1999; Grobelny et al., 2000; 
Wu et al., 2000; Molenaar et al., 2003; Wu et al., 2003), based 
on the observations that they contain telomeric DNA and pro-
teins involved in recombination and DNA repair (Yeager et al., 
1999; Wu et al., 2000; Yankiwski et al., 2000; Zhu et al., 2000, 
2003; Johnson et al., 2001; Stavropoulos et al., 2002; Wu et al., 
2003; Nabetani et al., 2004; Tarsounas et al., 2004), and that 
they are sites of DNA synthesis (Wu et al., 2000, 2003; Nabetani 
et al., 2004). However, the results from our study show that 
APBs are induced in growth-arrested, phenotypically senescent 
cells, and that HP1, which compacts heterochromatic DNA, is 
required for this process, suggesting that the telomeric DNA in-
side the APBs associated with growth arrest is in a state that is 
unlikely to permit telomere–telomere recombination. These data 
indicate that it is not likely that there is a simple correlation be-
tween the number of APB-positive cells in an ALT population 
and the level of ALT activity.
Materials and methods
Cell culture
The  spontaneously  immortalized  Li-Fraumeni  syndrome  fibroblast  line 
IIICF/c (Rogan et al., 1995) and SV40-immortalized human fibroblast lines 
JFCF-6/T.1J/1D and JFCF-6/T.1J/6B were cultured in DME (Invitrogen). 
The p53-ER fusion gene or ER-only transfected IIICF/c cell lines c/p53ER/7 
(C7), c/p53ER/8 (C8), and c/ER/2 (C2) were cultured in phenol red–free 
DME (Invitrogen) containing 1 µg/ml puromycin (Homer et al., 2005). 
IIICF cells immortalized with SV40 LTAg that was wt (IIICF-T/B3) or mutant 
(IIICF-402DE/D2) (Maclean et al., 1994) were cultured in RPMI 1640 me-
dium (Invitrogen). All culture media contained 10% fetal bovine serum 
(FBS) and 50 µg/ml gentamicin, and cultures were incubated in a 5% CO2 
humidified atmosphere at 37°C.
Table IV.  Proportion of APB-positive IIICF-T/B3 cells after siRNA 
treatment
siRNA treatment
a  Total (SV40T)
b APB+ (%)
SV40T + C 117 63 (53.8)
SV40T + HP1 111 40 (36.0)
SV40T + HP1-2  120 38 (31.7)
SV40T + HP1-1  123 56 (45.5)
SV40T + HP1-4 124 61 (49.2)
SV40T + HP1-2 109 38 (34.9)
SV40T + HP1-6 128 41 (32.0)
SV40T + C + C 94 53 (56.4)
SV40T + C + p21-6 98 25 (25.5)
SV40T + C + HP1 97 33 (34.0)
SV40T + C + HP1-1  100 47 (47.0)
SV40T + C + HP1-6  106 30 (28.3)
SV40T + HP1 + HP1-1  105 32 (30.5)
SV40T + HP1 + HP1-6  110 24 (21.8)
SV40T + HP1-1 + HP1-6  99 31 (31.3)
SV40T + C + C 111 58 (52.3)
SV40T + C + HP1-2 106 32 (30.2)
SV40T + HP1-2 + HP1-2 119 33 (27.7)
SV40T + HP1-2 + HP1-6 107 21 (19.6)
C, nonsilencing control siRNA.
aCells were treated with 10 nM siRNA per target for 4 d before being fixed for 
immunostaining.
bOnly cells that were negative by immunostaining for SV40T were examined 
for APBs.JCB • VOLUME 185 • NUMBER 5 • 2009   808
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Double staining of telomeric DNA and APB-associated proteins was 
performed as described previously (Henson et al., 2005). In brief, slides 
were first immunostained with primary and secondary antibodies, then cross-
linked with 4% formaldehyde and dehydrated. Telomere FISH was done by 
using a Cy3-conjugated telomere-specific peptide nucleic acid probe   
(Applied Biosystems).
The samples were examined at room temperature on a fluores-
cence microscope (DMLB; Leica). A Plan-Fluotar 40×/0.7 NA objective 
lens and a Plan-Fluotar 10×/0.3 NA objective lens (Leica) were used in 
this study. Images were recorded using a cooled charge-coupled device 
camera (SPOT2; Diagnostic Instruments, Inc.) with SPOT image acquisi-
tion software (Diagnostic Instruments, Inc.), and analyzed with Photoshop 
6.0 (Adobe). The contrast/brightness of images was adjusted uniformly 
across the field.
SA--gal activity assay
Cells were grown in four-well chamber slides to 30–40% confluency and then 
treated with 1 µM 4OHT or 10 nM SV40T siRNA for 3 or 4 d. The SA--gal 
staining was performed with a SA--gal staining kit (Cell Signaling Technol-
ogy) according to the manufacturer’s instructions. The samples were exam-
ined on an inverted microscope (IMT-2; Olympus) with an A10PL 10×/0.25 
NA objective lens (Olympus). Images were recorded using a digital camera 
(DP12; Olympus) and analyzed with Photoshop 6.0.
Immunoblotting
For immunoblotting analyses, cell lysates were prepared, electrophoretically 
separated on SDS-PAGE gels, and electrotransferred to a nylon membrane 
as described previously (Toouli et al., 2002). Immunoblotting procedures 
were performed as recommended by the antibody suppliers. HRP-conjugated 
goat anti–mouse, goat anti–rabbit, swine anti–rabbit, or rabbit anti–goat 
IgG (Dako) were used as secondary antibodies.
Online supplemental material
Fig. S1 shows induction of a senescent phenotype in SV40-immortalized 
ALT cells upon treatment with SV40T siRNA. Fig. S2 shows the associa-
tion of APB induction with p53/p21-mediated growth arrest/senescence. 
Fig.  S3  shows  that  there  is  no  APB  induction  in  SV40-immortalized 
telomerase-positive cells. Fig. S4 shows the presence of p21, PCNA, and 
Cdk2 within APBs. Fig. S5 shows the requirement of HP1 for APB formation 
in p53-negative IIICF/c cells. Table S1 shows the proportion of APB-
positive cells after methionine starvation. Table S2 shows the proportion of 
APB+ cells containing p21+ APBs after induction of p53. Table S3 shows 
the proportion of APB-positive IIICF/c cells after siRNA-treatment and methio-
nine restriction. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.200810084/DC1.
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